SciBase Supports Clinicians During US Skin Cancer Awareness Month
SciBase Supports Clinicians During US Skin Cancer Awareness Month
STOCKHOLM, May 2, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a pioneer in skin cancer detection and prevention, and prediction in dermatology, further deepens their commitment to patients and dermatologists during US Skin Cancer Awareness Month by highlighting the importance of early detection and prevention of skin cancer and helping improve outcomes for clinicians and patients.
斯德哥爾摩，2024 年 5 月 2 日 /PRNewswire/-- SciBase Holding AB（“SciBase”） （停止：SCIB），皮膚癌檢測和預防以及皮膚病學預測領域的先驅， 在美國皮膚癌宣傳月期間，通過強調及早發現和預防皮膚癌的重要性以及幫助改善臨床醫生和患者的預後，進一步加深他們對患者和皮膚科醫生的承諾。
The entire month of May is dedicated to Skin Cancer Awareness to draw focus on the most common cancer in the United States - skin cancer. It is estimated that more than 9,500 people are diagnosed with skin cancer every day and over 200,000 people are diagnosed with melanoma every year. Melanoma is the most dangerous and lethal form of skin cancer and accounts for the vast majority of skin cancer deaths. A good portion of these skin cancers may be prevented if people were to protect their skin from the sun and tanning beds, practice healthy skin habits, and visit a dermatologists at least once a year for a full body skin exam. When detected early, skin cancer is highly curable making early detection key to survival.
五月的整個月都致力於提高對皮膚癌的認識，以吸引人們對美國最常見的癌症——皮膚癌的關注。據估計，每天有超過9,500人被診斷出患有皮膚癌，每年有超過20萬人被診斷出患有黑色素瘤。黑色素瘤是皮膚癌中最危險和最致命的形式，佔皮膚癌死亡人數的絕大多數。如果人們保護自己的皮膚免受陽光和日光浴牀的侵害，養成健康的皮膚習慣，每年至少去看一次皮膚科醫生進行全身皮膚檢查，那麼這些皮膚癌的很大一部分是可以預防的。如果及早發現，皮膚癌是高度可治癒的，因此早期發現是存活的關鍵。
"Melanoma is one of the top 10 most common cancers in the US. With melanoma, early detection is vital to improving clinical outcomes for patients. For these reasons, I am using the AI-powered Nevisense test in my clinical practice. I recently performed a Nevisense test on a mole that I was hesitant to biopsy, and the technology provided me with real-time, non-invasive data right there during that visit. I immediately integrated the Nevisense data into my biopsy decision, and detected a melanoma in situ on this patient much sooner than I would have otherwise. This technology positively impacted the clinical outcome for both my patient and for me as a clinician," said Dr. Brad Yentzer, Founder and CEO of Finger Lakes Dermatology in New York.
“黑色素瘤是美國十大最常見的癌症之一。對於黑色素瘤，早期發現對於改善患者的臨床療效至關重要。出於這些原因，我在臨床實踐中使用人工智能驅動的Nevisense測試。我最近對一隻我猶豫不決的痣進行了Nevisense測試，在那次就診期間，該技術爲我提供了實時、非侵入性的數據。我立即將Nevisense數據整合到我的活檢決定中，並比原本更快地在這位患者身上發現了黑色素瘤。這項技術對我的患者和我作爲臨床醫生的臨床結果產生了積極影響。” 紐約Finger Lakes皮膚科創始人兼首席執行官布拉德·延策博士說。
"Most skin cancers are curable if they are detected and treated early enough. Because of this, skin cancer education and the importance of full body skin exams by board certified dermatologists on patients at risk, are critical to early detection and survival," said Dr. Mark Kaufmann, Clinical Professor in the Department of Dermatology at the Icahn School of Medicine at Mount Sinai, and Chief Medical Officer of Advanced Dermatology and Cosmetic Surgery in Florida, and former President of The American Academy of Dermatology (2022-23).
“如果儘早發現和治療，大多數皮膚癌是可以治癒的。因此，皮膚癌教育以及由委員會認證的皮膚科醫生對高危患者進行全身皮膚檢查的重要性對於早期發現和存活至關重要。” 西奈山伊坎醫學院皮膚科臨床教授、佛羅里達州高級皮膚病學和整容外科首席醫學官、美國皮膚科學會前院長（2022-23）馬克·考夫曼博士說。
"Early detection is key to improving patient outcomes and survival. At SciBase, our emphasis on skin cancer awareness month demonstrates how seriously we take the importance of patients having an annual full body skin exam performed by a dermatologist. We are deeply dedicated to supporting the early detection of skin cancer at its most curable stage-when it matters and can make a life-altering impact-and helping to improve outcomes for clinicians and patients," said Pia Renaudin, CEO of SciBase.
“早期發現是改善患者預後和存活率的關鍵。在SciBase，我們對皮膚癌宣傳月的重視表明我們非常重視患者每年由皮膚科醫生進行全身皮膚檢查的重要性。SciBase首席執行官皮亞·雷諾丁說，我們致力於支持皮膚癌在最可治癒的階段的早期發現——這時皮膚癌很重要，可以改變生活，並幫助改善臨床醫生和患者的預後。
For additional information, please contact:
Pia Renaudin, VD, tel. +46732069802, e-mail: [email protected]
欲了解更多信息，請聯繫：
Pia Renaudin，VD，電話 +46732069802，電子郵件：[email protected]
Certified Advisor (CA):
Vator Securities
Tel: +46 8 580 065 99
Email: [email protected]
認證顧問 (CA)：
Vator 證券
電話：+46 8 580 065 99
電子郵件：[電子郵件保護]
About SciBase
關於 SciBase
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
SciBase 是一家全球醫療技術公司，專門從事皮膚病學的早期發現和預防。SciBase 開發並商業化了 Nevisense，這是一個獨特的即時護理平台，它結合了人工智能（人工智能）和先進的 EIS 技術，可提高診斷準確性，確保積極的皮膚健康管理。
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
我們的承諾是最大限度地減少患者的痛苦，使臨床醫生能夠通過及時的檢測和干預來改善和挽救生命，並降低醫療成本。
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
SciBase建立在瑞典斯德哥爾摩卡羅林斯卡研究所20多年的研究基礎上，是皮膚病學進步領域的領導者。
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at . All press releases and financial reports can be found here:
該公司自2015年6月2日起在納斯達克第一北方成長市場交易所上市。要了解更多，請訪問。 所有新聞稿和財務報告都可以在這裏找到：
This information was brought to you by Cision
這些信息是由 Cision 帶給你的
譯文內容由第三人軟體翻譯。